---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009722"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:33.656480+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beam reports $1.25B cash, FDA alignment on BEAM-302 accelerated path; risto-cel BLA expected year-end 2026

## Summary
- Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.
- FDA alignment on potential accelerated approval for BEAM-302 based on AAT biomarkers over 12 months; ~50 additional patients to be enrolled.
- BLA submission for risto-cel (formerly BEAM-101) expected as early as year-end 2026; BEACON trial fully enrolled, manufacturing done December 2025.
- Updated BEAM-302 Phase 1/2 data and pivotal plan expected by end of Q1 2026; new liver-targeted program to be announced H1 2026.
- Initial BEAM-301 clinical data expected in 2026; BEAM-103 Phase 1 healthy volunteer trial to complete dosing in H1 2026.

## SEC filing metadata
- accession: 0001193125-26-009722
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312526009722/0001193125-26-009722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312526009722/beam-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009722
- JSON: https://secwatch.observer/filing/0001193125-26-009722.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.